Frequently Asked Questions

ODT's platform has been demonstrated to work with a variety of actives including  ulcer treatments/ preventatives, antibiotics, analgesics, NSAIDs, bronchodilators, parasiticides and tranquilizers.   

The platform's ability to work with a specific active is driven by the molecular size, polarity, dose size and the ability of the active to move across the mucosal membrane.

No, animals are unable to spit out the tablet. Tablets dissolve in under 2 seconds  and, in fact, the act of trying the spit out the tablet will cause the tablet to disintegrate faster.

ODT's platform will work across a wide variety of active ingredients, both novel and existing APIs.

As the ODT  platform is novel in Animal Health, the pharmacokinetics (PK) will be different from prior products iterations, likely requiring the product to be registered as a new animal drug with the United  States Food and Drug Administration Center for Veterinary Medicine. 

ODT's platform is manufactured in a facility that also produces human products for global markets.  The facility is FDA inspected and EMEA certified.

Some countries impose restrictions on manufacturing human and animal products in the same facility, which may limit the availability of certain actives to be developed for  animal health.